Beyond the Plaque

For thirty years, the dominant hypothesis in Alzheimer’s research narrowed the field to a single mechanism, and the cost of that narrowing is now visible: large meta-analyses of plaque-clearing antibodies confirm no clinically meaningful cognitive benefit, Manufacturing Chemist despite the plaques being cleared. The Alzheimer’s Institute is built so that pattern cannot repeat. Twelve specialized agents reason in parallel across genetics, tau, TDP-43, neuroinflammation, synaptic biology, vascular and glymphatic dysfunction, metabolic signaling, and well-characterized repurposing candidates. Patient subtyping uses modern CSF proteomic and imaging signatures, including the recognition of APOE4 homozygosity as a genetically determined form of the disease. PubMed Every hypothesis passes a causal gate. An anti-monoculture operator forbids the population of active hypotheses from collapsing onto any single mechanism. Patient-iPSC and organoid models replace the transgenicmouse default. The institute is structured around FDA-aligned credibility methodology and the joint AI-in-drug-development guiding principles now shared across U.S. and European regulators.

Value proposition:

• Multi-mechanism reasoning, no monoculture
• Patient-iPSC and organoid models as default
• Regulator-aligned credibility from day one